Anthranilic Acid Amides: A Novel Class of Antiangiogenic VEGF Receptor Kinase Inhibitors
Citations Over TimeTop 12% of 2002 papers
Abstract
Two readily synthesized anthranilamide, VEGF receptor tyrosine kinase inhibitors have been prepared and evaluated as angiogenesis inhibitors. 2-[(4-Pyridyl)methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide (5) and N-3-isoquinolinyl-2-[(4-pyridinylmethyl)amino]benzamide (7) potently and selectively inhibit recombinant VEGFR-2 and VEGFR-3 kinases. As a consequence of their physicochemical properties, these anthranilamides readily penetrate cells and are absorbed following once daily oral administration to mice. Both 5 and 7 potently inhibit VEGF-induced angiogenesis in an implant model, with ED(50) values of 7 mg/kg. In a mouse orthotopic model of melanoma, 5 and 7 potently inhibited both the growth of the primary tumor as well as the formation of spontaneous peripheral metastases. The anthranilamides 5 and 7 represent a new structural class of VEGFR kinase inhibitors, which possess potent antiangiogenic and antitumor properties.
Related Papers
- → Localizations of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptor 2 (VEGFR2/Flk-1) during Mouse Tooth Development(2003)1 cited
- → 589 N-myc downstream regulated gene 1 (NDRG1) as a novel anti-angiogenic and therapeutic target for VEGF/VEGF receptor signaling by vascular endothelial cells(2014)
- → VEGF; VEGF receptor 1 (FLT1; VEGFR-1); VEGFR-2 (KDR/Flk-1)(2013)
- → The Vascular Endothelial Growth Factor (VEGF) Receptor Flt-1 (VEGFR-1) Modulates Flk-1 (VEGFR-2) Signaling During Blood Vessel Formation(2020)